Insmed initiates three Phase 3 trials of TPIP for pulmonary diseases

• Insmed will feature its four-study Phase 3 PALM program for treprostinil palmitil inhalation powder at CHEST 2026.
• Three trials have begun; the fourth, PALM-IPF, is expected to start in the first half of 2027.
• The program aims to enroll more than 2,000 patients to evaluate once-daily treatment for pulmonary hypertension and fibrotic lung diseases.
• Earlier Phase 2 studies yielded clinically meaningful efficacy and safety findings in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
• The Phase 3 trials will assess whether treatment improves exercise capacity or preserves lung function across the targeted diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610150700PR_NEWS_USPR_____NY72509) on October 15, 2026, and is solely responsible for the information contained therein.